John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Anti-EGFR versus anti-VEGF in first line chemotherapy in metastatic colorectal cancer: an explosive match Volume 21, issue 7, Septembre 2014

Figures

  • Figure 1
  • Figure 2
Author
CHU de Poitiers, service d’hépato-gastro-entérologie, 2 rue de la Milétrie, 86000 Poitiers Cedex, France

Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: A randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol March 31, 2014.